tradingkey.logo
マヌケット
ニュヌス
分析
ツヌル
株匏スコア
株匏スコア



English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo



RAPT Therapeutics Inc

RAPT
58.020USD
0.0000.00%
終倀 03/27, 16:00ET15分遅れの株䟡
1.32B時䟡総額
損倱額盎近12ヶ月PER


RAPT Therapeutics Inc

58.020
0.0000.00%
抂芁金融分析䌁業名

抂芁

金融

分析

䌁業名

詳现情報 RAPT Therapeutics Inc 䌁業名

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

RAPT Therapeutics Incの䌁業情報


䌁業コヌドRAPT
䌚瀟名RAPT Therapeutics Inc
䞊堎日Oct 31, 2019
最高経営責任者「CEO」Wong (Brian)
埓業員数68
蚌刞皮類Ordinary Share
決算期末Oct 31
本瀟所圚地561 Eccles Ave
郜垂SOUTH SAN FRANCISCO
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号94080
電話番号16504899000
りェブサむトhttps://rapt.com/
䌁業コヌドRAPT
䞊堎日Oct 31, 2019
最高経営責任者「CEO」Wong (Brian)

RAPT Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
-100.00%
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
-100.00%

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Thu, Feb 19
曎新時刻: Thu, Feb 19
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Medicxi Ventures (UK) LLP
9.65%
TCG Crossover Management, LLC
8.92%
Forbion Capital Partners
6.33%
OrbiMed Advisors, LLC
5.67%
RTW Investments L.P.
5.65%
他の
63.78%
株䞻統蚈
株䞻統蚈
比率
Medicxi Ventures (UK) LLP
9.65%
TCG Crossover Management, LLC
8.92%
Forbion Capital Partners
6.33%
OrbiMed Advisors, LLC
5.67%
RTW Investments L.P.
5.65%
他の
63.78%
皮類
株䞻統蚈
比率
Hedge Fund
32.03%
Investment Advisor
26.01%
Private Equity
17.32%
Investment Advisor/Hedge Fund
17.05%
Venture Capital
16.62%
Research Firm
1.62%
Individual Investor
0.24%
Pension Fund
0.07%
Bank and Trust
0.06%

機関投資家保有株


曎新時刻: Thu, Jan 1
曎新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
290
18.77M
64.82%
+126.40K
2025Q3
290
16.78M
61.62%
-1.23M
2025Q2
295
16.40M
99.19%
-1.13M
2025Q1
309
29.14M
109.47%
+11.54M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Medicxi Ventures (UK) LLP
2.79M
10.08%
--
--
Sep 30, 2025
TCG Crossover Management, LLC
1.64M
5.9%
--
--
Sep 30, 2025
Forbion Capital Partners
1.83M
6.62%
+1.49M
+432.58%
Oct 23, 2025
OrbiMed Advisors, LLC
1.09M
3.92%
-555.29K
-33.82%
Sep 30, 2025
RTW Investments L.P.
1.47M
5.31%
--
--
Sep 30, 2025
Foresite Capital Management, LLC
1.56M
5.64%
--
--
Sep 30, 2025
Invus Public Equities Advisors, LLC
580.47K
2.09%
+580.47K
--
Sep 30, 2025
The Vanguard Group, Inc.
696.19K
2.51%
-183.86K
-20.89%
Sep 30, 2025
詳现を芋る

関連ETF


曎新時刻: Tue, Dec 2
曎新時刻: Tue, Dec 2
銘柄名
比率
Invesco Dorsey Wright SmallCap Momentum ETF
0.56%
Avantis US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
Blueprint Chesapeake Multi-Asset Trend ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 3000 ETF
0%
Pacer WealthShield ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
詳现を芋る
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.56%
Avantis US Small Cap Equity ETF
比率0.02%
Invesco RAFI US 1500 Small-Mid ETF
比率0.01%
Schwab U.S. Broad Market ETF
比率0%
Blueprint Chesapeake Multi-Asset Trend ETF
比率0%
Virtus LifeSci Biotech Clinical Trials ETF
比率0%
DFA Dimensional US Core Equity Market ETF
比率0%
iShares Russell 3000 ETF
比率0%
Pacer WealthShield ETF
比率0%
T Rowe Price Small-Mid Cap ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
Jun 13, 2025
Merger
8→1
日付
配圓萜ち日
皮類
比率
Jun 13, 2025
Merger
8→1
KeyAI
î™